Literature DB >> 24306327

Pharmacological characterization of 7-(4-(Piperazin-1-yl)) ciprofloxacin derivatives: antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity.

Béatrice Marquez1, Vincent Pourcelle, Coralie M Vallet, Marie-Paule Mingeot-Leclercq, Paul M Tulkens, Jacqueline Marchand-Bruynaert, Françoise Van Bambeke.   

Abstract

PURPOSE: To evaluate pharmacological properties (antibacterial activity; accumulation in phagocytic cells; activity against intracellular bacteria; susceptibility to fluoroquinolone efflux transporters) of ciprofloxacin derivatives modified at C-7 of the piperazine ring.
METHODS: N-acetyl- (1), N-benzoyl- (2), N-ethyl- (3), and N-benzyl- (4) ciprofloxacin were synthesized. MICs against Escherichia coli and Staphylococcus aureus were determined following CLSI guidelines. Cellular accumulation, subcellular distribution, and intracellular activity (towards S. aureus and Listeria monocytogenes) were determined in J774 mouse macrophages. Efflux in bacteria (NorA [S. aureus], Lde [L. monocytogenes]) and in macrophages (Mrp4) was assessed using the corresponding inhibitors reserpine and gemfibrozil, respectively.
RESULTS: All derivatives were active, though less than ciprofloxacin. 2 and 3 accumulated 2-3 fold more than ciprofloxacin in mouse macrophages but remained substrates for efflux by Mrp4. 4 was insensitive to NorA and Lde, accumulated approx 50-fold more than ciprofloxacin in macrophages, was barely affected by Mrp4, localized in the soluble fraction of cells, and was equipotent to ciprofloxacin against intracellular bacteria.
CONCLUSIONS: Benzyl substitution at C7 markedly affects the pharmacological profile of ciprofloxacin with respect to recognition by efflux transporters and cellular accumulation. N-benzyl-ciprofloxacin may serve as basis for designing molecules with higher intrinsic activity while remaining poorly susceptible to efflux.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24306327     DOI: 10.1007/s11095-013-1250-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  39 in total

1.  Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).

Authors:  I S Haslam; J A Wright; D A O'Reilly; D J Sherlock; T Coleman; N L Simmons
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

2.  Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion.

Authors:  Gracia Merino; Ana I Alvarez; Mivis M Pulido; Antonio J Molina; Alfred H Schinkel; Julio G Prieto
Journal:  Drug Metab Dispos       Date:  2006-01-24       Impact factor: 3.922

3.  Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages.

Authors:  Jean-Michel Michot; Marie F Heremans; Nancy E Caceres; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 4.  Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples.

Authors:  H Nikaido; D G Thanassi
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

5.  Development and validation of an HPLC method for the determination of gatifloxacin stability in human plasma.

Authors:  Saleh Al-Dgither; Syed Naseeruddin Alvi; Muhammad M Hammami
Journal:  J Pharm Biomed Anal       Date:  2005-11-28       Impact factor: 3.935

6.  Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter.

Authors:  A A Neyfakh; C M Borsch; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

7.  The effect of temperature and pH on the solubility of quinolone compounds: estimation of heat of fusion.

Authors:  X Yu; G L Zipp; G W Davidson
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

8.  Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus.

Authors:  Cristina Seral; Stéphane Carryn; Paul M Tulkens; Françoise Van Bambeke
Journal:  J Antimicrob Chemother       Date:  2003-04-14       Impact factor: 5.790

9.  Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Authors:  Cristina Seral; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Synthesis and antibacterial activity of new N-[2-(thiophen-3-yl)ethyl] piperazinyl quinolones.

Authors:  Bahram Letafat; Saeed Emami; Negar Mohammadhosseini; Mohammad Ali Faramarzi; Nasrin Samadi; Abbas Shafiee; Alireza Foroumadi
Journal:  Chem Pharm Bull (Tokyo)       Date:  2007-06       Impact factor: 1.645

View more
  1 in total

Review 1.  Fluoroquinolones' Biological Activities against Laboratory Microbes and Cancer Cell Lines.

Authors:  Ghadeer A R Y Suaifan; Aya A M Mohammed; Bayan A Alkhawaja
Journal:  Molecules       Date:  2022-03-03       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.